Ultragenyx Pharmaceutical RARE reported new findings from an ongoing, pivotal study of its investigational candidate, UX111 (ABO-102) AAV gene therapy, for Sanfilippo syndrome type A (MPS IIIA). Per ...

Amidst a backdrop of fluctuating global markets, the U.S. technology sector has faced notable volatility, driven by competitive pressures in artificial intelligence and mixed corporate earnings ...

INNOVENT BIO (01801.HK)'s total product revenue for 2024 amounted to more than RMB8.2 billion, representing a robust YoY ...

After combing through 4,000 existing medications, an artificial intelligence tool helped uncover one that saved the life of a patient with idiopathic multicentric Castleman's disease (iMCD).

The stock is trading at 1.0150, up 0.6573, gaining 183.7573% on volume of over 422 Million shares, with a day's high of $1.11. The stock announced breaking news on its Monoclonal Antibody designed to ...

Drugs and medicines under Patient Assistance Programmes run by pharmaceutical companies were being made fully exempt from ...

The list of 36 drugs, which are exempt from basic customs duty, includes many expensive and imported medicines that can ...

Six other drugs will have a concessional customs duty of 5% as part of efforts to increase accessibility of expensive advanced medicines for a larger section of patients ...

Novartis has finally given up on iscalimab after deciding that the anti-CD40 antibody is not worth pursuing in Sjögren’s syndrome. | Novartis has finally given up on iscalimab after deciding that the ...

We recently compiled a list of the Jim Cramer Shed Light on These 9 Stocks. In this article, we are going to take a look at ...

Minot Light Capital, an investment management firm, recently released its fourth-quarter 2024 investor letter. A copy of the ...

Fact checked by Nick Blackmer Two Alzheimer's drugs that target amlyoid plaques have been approved for months, but many hospitals are only now starting to offer these treatments. Leqembi ...